A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

Table 3 Toxicities in stage II patients who received h-R3/RT or CDDP/RT (N = 26)

Toxicities (RTOG Grade)	h-R3/RT (N = 13) [n (%)]	CDDP/RT (N = 13) [n (%)]	P Value*
WBC			0.711
(1&2)	10 (76.9%)	6 (46.2%)
(3&4)	0 (0.0%)	3 (23.1%)
PLT			0.380
(1&2)	6 (46.2%)	6 (46.2%)
(3&4)	0 (0.00%)	1 (7.7%)
HB			0.083
(1&2)	8 (61.5%)	5 (61.5%)
(3&4)	0 (0.0%)	0 (0.0%)
ALT			0.655
(1&2)	2 (15.4%)	3 (23.1%)
(3&4)	0 (0.0%)	0 (0.0%)
AST			0.157
(1&2)	2 (15.4%)	0 (0.0%)
(3&4)	0 (0.0%)	0 (0.0%)
GGT			1.000
(1&2)	1 (7.7%)	1 (7.7%)
(3&4)	0 (0.0%)	0 (0.0%)
Dermatitis			0.414
(1&2)	8 (61.5%)	11 (84.6%)
(3&4)	0 (0.0%)	0 (0.0%)
Rash			0.655
(1&2)	3 (23.1%)	2 (15.4%)
(3&4)	0 (0.0%)	0 (0.0%)
Mucositis			0.093
(1&2)	5 (38.5%)	8 (61.5%)
(3&4)	7 (53.8%)	5 (38.5%)
Taste change			1.000
yes	13 (100%)	13 (100%)
no	0 (0.0%)	0 (0.0%)
Vomit			0.046*
only nausea	6 (46.2%)	3 (23.1%)
Nausea and vomit	2 (15.4%)	10 (76.9%)
Weight loss			0.305
(1&2)	8 (61.6%)	7 (53.8%)
(3&4)	3 (23.1%)	5 (38.5%)

Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy
*All p values were obtained using the paired rank sum test

ISSN: 1471-2407